ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0744

Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus

May Choi1, Hongshu Guan2, Kazuki Yoshida3, Benjamin Kargere4, Jack Ellrodt5, Emma Stevens2, Tianrun Cai2, Brendan Everett2, Brittany Weber2 and Karen Costenbader6, 1University of Calgary, Calgary, AB, Canada, 2Brigham and Women's Hospital, Boston, MA, 3Takeda, Boston, MA, 4Williams College, Boston, MA, 5Williams College, Williamstown, MA, 6Brigham and Women's Hospital and Harvard Medical School, Boston, MA

Meeting: ACR Convergence 2023

Keywords: Cardiovascular, Myocardial Infarction, risk assessment, Stroke, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: Abstracts: Epidemiology & Public Health I

Session Type: Abstract Session

Session Time: 2:00PM-3:30PM

Background/Purpose: Cardiovascular disease (CVD) risk is elevated in patients with SLE but underestimated by current general population prediction algorithms that do not include SLE-related variables. We aimed to develop a novel SLE-specific prediction tool, SLECRISK, to estimate CVD risk more accurately in SLE.

Methods: We studied patients in the Brigham and Women’s Hospital SLE cohort. We collected 1-year baseline data on traditional CVD risk factors, demographic and SLE-related clinical features from the electronic medical records at cohort enrollment. Ten-year follow-up for 1stmajor adverse cardiovascular event (MACE, non-fatal myocardial infarction [MI], non-fatal stroke, and cardiac death) began at day +1 after baseline period (index date). ICD-9/10 codes identified MACE, adjudicated by medical record review by board-certified cardiologists. Least absolute shrinkage and selection operator (LASSO) regression selected SLE-related variables to add to the American College of Cardiology (ACC)/American Heart Association (AHA) Pooled Cohort Risk Equations 10-year risk Cox regression model. Model fit statistics and performance for predicting moderate- and high-risk (≥10%) of MACE were assessed and compared to ACC/AHA alone, Framingham risk score (FRS), and modified FRS (FRS multiplied by 2, mFRS). Optimism adjustment was performed using bootstrapping with 300 samples.

Results: We included 1,243 patients with 90 MACEs (46 MIs, 36 strokes, 19 cardiac deaths) over 8,946.5 person-years follow-up (Table 1).

Our best SLECRISK 10-Year CVD Risk equation was: 1-0.92*exp(βx-1.84), whereby βx = 5.44*Base ACC/AHA Risk Score + 0.31*disease activity (remission/mild vs. moderate/severe) + 0.04*disease duration (years) + 0.17*Creatinine (mg/dL) + 0.35*Anti-dsDNA + 0.22*Anti-RNP + 0.47*Lupus anticoagulant + 0.31*Anti-Ro + 0.49*low C4.

Sensitivity for detecting moderate/high-risk (≥10%) of MACE (0.64) and c-statistic for model discrimination (0.76) were improved vs. traditional models (Table 2). The AIC estimate of model fit improved (1190.5 to 1162.2) and Hosmer-Lemeshow goodness-of-fit tests yielded favorable results (P 0.02 in base ACC/AHA model and P 0.77 in SLECRISK), indicating good model calibration. SLECRISK identified >3-fold more high-risk patients, particularly more young women with few traditional risk factors, but more severe SLE, including lupus nephritis, higher creatinine, more autoantibodies, including antiphospholipid antibodies, hypocomplementemia, and more taking azathioprine (Fig 1).

Conclusion: We derived and internally validated a novel SLE-specific CVD risk tool based on the ACC/AHA score and SLE-related factors. SLECRISK was more sensitive and accurate than the traditional CVD generic tools for predicting moderate- and high-risk for MACE over 10 years of follow-up. If externally validated, SLECRISK may be incorporated into SLE management guidelines to help guide decision-making in the primary prevention of CVD in clinical practice.

Supporting image 1

Supporting image 2

Supporting image 3

Figure 1. Risk Classification (%) by Cardiovascular Risk Prediction Models as Low (<10%), Moderate (10_20%), and High (>20%) Ten-year MACE Risk of Definite and Probable MACE among 1,243 Patients with SLE at Baseline. Abbreviations: ACC/AHA, American College of Cardiology/American Heart Association; mFRS, FRS Framingham risk score; modified Framingham risk score


Disclosures: M. Choi: AbbVie/Abbott, 2, 6, Amgen, 2, 6, AstraZeneca, 2, 6, Bristol-Myers Squibb(BMS), 2, 6, Celgene, 2, 6, Eli Lilly, 2, 6, GlaxoSmithKlein(GSK), 2, Janssen, 2, 6, Mallinckrodt, 2, Merck/MSD, 2, MitogenDx, 2, Organon, 6, Pfizer, 2, 6, Roche, 2, Werfen, 2; H. Guan: None; K. Yoshida: Takeda, 3; B. Kargere: None; J. Ellrodt: None; E. Stevens: None; T. Cai: None; B. Everett: None; B. Weber: Bristol-Myers Squibb(BMS), 1, Horizon Therapeutics, 1, Kiniksa, 1, Novo Nordisk, 1; K. Costenbader: Amgen, 2, 5, AstraZeneca, 5, Bristol-Myers Squibb(BMS), 2, Cabaletta, 2, Eli Lilly, 2, Exagen Diagnostics, 5, Gilead, 5, GlaxoSmithKlein(GSK), 2, 5, Janssen, 2, 5.

To cite this abstract in AMA style:

Choi M, Guan H, Yoshida K, Kargere B, Ellrodt J, Stevens E, Cai T, Everett B, Weber B, Costenbader K. Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/personalizing-cardiovascular-risk-prediction-for-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/personalizing-cardiovascular-risk-prediction-for-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology